BC Week In Review | Nov 30, 2018
Company News

Pfizer extends Lyrica exclusivity by six months in U.S.

Pfizer Inc. (NYSE:PFE) said FDA granted pediatric exclusivity to its blockbuster neurology drug Lyrica pregabalin, extending the product's patent protection by six months to June 30, 2019. Lyrica is approved in the U.S. to treat...
BC Innovations | Dec 13, 2017
Distillery Therapeutics

Ophthalmic disease

INDICATION: Ocular hypertension Mouse studies suggest inhibiting CACNA2D1 could help treat ocular hypertension. In a mouse model of ocular hypertension, Lyrica pregabalin, which inhibits CACNAD21, decreased intraocular pressure compared with no treatment. Next steps could...
BC Innovations | Sep 14, 2017
Strategy

Numerate’s Intelligence

With three new partnerships formed since June, Numerate Inc. is picking up steam and demonstrating that industry and academic groups alike are finding utility in its AI platform, which can build robust predictive models for...
BC Innovations | May 2, 2013
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Liver cancer Calcium channel voltage-dependent a2/d subunit 1 (CACNA2D1) Mouse and in vitro studies suggest targeting CACNA2D1 could help treat hepatocellular...
Items per page:
1 - 4 of 4